| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | RG-108 | CTRPv2 | pan-cancer | AAC | 0.08 | 0.03 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | 0.17 | 0.03 |
| mRNA | Imatinib | CTRPv2 | pan-cancer | AAC | -0.08 | 0.03 |
| mRNA | Compound 1541A | CTRPv2 | pan-cancer | AAC | 0.087 | 0.03 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | -0.07 | 0.04 |
| mRNA | ATRA | CTRPv2 | pan-cancer | AAC | 0.075 | 0.04 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.072 | 0.04 |
| mRNA | GDC-0879 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.04 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.064 | 0.04 |
| mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | 0.082 | 0.04 |